Full Text of SB0697 102nd General Assembly
SB0697 102ND GENERAL ASSEMBLY |
| | 102ND GENERAL ASSEMBLY
State of Illinois
2021 and 2022 SB0697 Introduced 2/25/2021, by Sen. Laura Fine SYNOPSIS AS INTRODUCED: |
| 215 ILCS 5/370c | from Ch. 73, par. 982c | 215 ILCS 180/35 | | 215 ILCS 180/40 | |
|
Amends the Illinois Insurance Code. Provides that every insurer that amends, delivers, issues, or renews a group or individual policy of accident and health insurance or a qualified health plan offered through the health insurance marketplace in the State and Medicaid managed care organizations providing coverage for hospital or medical treatment shall provide coverage for medically necessary treatment of mental, emotional, nervous, or substance use disorders or conditions. Provides that an insurer shall not limit benefits or coverage for medically necessary services on the basis that those services should be or could be covered by a public program. Provides that an insurer shall base any medical necessity determination or the utilization review criteria on current generally accepted standards of mental, emotional, nervous, or substance use disorder or condition care. Provides that in conducting utilization review of covered health care services and benefits for the diagnosis, prevention, and treatment of mental, emotional, and nervous disorders or conditions in children, adolescents, and adults, an insurer shall exclusively apply the criteria and guidelines set forth in the most recent versions of the treatment criteria developed by the nonprofit professional association for the relevant clinical specialty. Provides that an insurer shall not apply different, additional, conflicting, or more restrictive utilization review criteria than the criteria and guidelines set forth in the treatment criteria. Provides that the Director may, after appropriate notice and opportunity for hearing, assess a civil penalty between $5,000 and $20,000 for each violation. Amends the Health Carrier External Review Act. Provides that independent review organization shall comply with specified requirements for an adverse determination or final adverse determination involving mental, emotional, nervous, or substance use disorders or conditions. Makes other changes. Effective immediately.
|
| |
| | A BILL FOR |
|
| | | SB0697 | | LRB102 17144 BMS 22576 b |
|
| 1 | | AN ACT concerning regulation.
| 2 | | Be it enacted by the People of the State of Illinois,
| 3 | | represented in the General Assembly:
| 4 | | Section 1. This Act may be referred to as the Generally | 5 | | Accepted Standards of Behavioral Health Care Act of 2021. | 6 | | Section 2. The General Assembly finds and declares the | 7 | | following:
| 8 | | (a) The State of Illinois and the entire country faces a | 9 | | mental health and addiction crisis.
| 10 | | (1) One in 5 adults experience a mental health | 11 | | disorder, and data from 2017 shows that one in 12 had a | 12 | | substance use disorder. The COVID-19 pandemic has | 13 | | exacerbated the nation's mental health and addiction | 14 | | crisis. According the U.S. Center for Disease Control and | 15 | | Prevention, since the start of the COVID-19 pandemic, | 16 | | Americans have experienced higher rates of depression, | 17 | | anxiety, and trauma, and rates of substance use and | 18 | | suicidal ideation have increased.
| 19 | | (2) Nationally, the suicide rate has increased 35% in | 20 | | the past 20 years. According to the Illinois Department of | 21 | | Public Health, more than 1,000 Illinoisans die by suicide | 22 | | every year, including 1,439 deaths in 2019, and it is the | 23 | | third leading cause of death among young adults aged 15 to |
| | | SB0697 | - 2 - | LRB102 17144 BMS 22576 b |
|
| 1 | | 34.
| 2 | | (3) Between 2013 and 2019, Illinois saw a 1,861% | 3 | | increase in synthetic opioid overdose deaths and a 68% | 4 | | increase in heroin overdose deaths. In 2019 alone, there | 5 | | were 2.3 and 2 times as many opioid deaths as homicides and | 6 | | car crash deaths, respectively.
| 7 | | (4) Communities of color are disproportionately | 8 | | impacted by lack of access to and inequities in mental | 9 | | health and substance use disorder care.
| 10 | | (A) According to the Substance Abuse and Mental | 11 | | Health Services Administration, two-thirds of Black | 12 | | and Hispanic Americans with a mental illness and | 13 | | nearly 90% with a substance use disorder do not | 14 | | receive medically necessary treatment.
| 15 | | (B) Data from the U.S. Census Bureau demonstrates | 16 | | that Black Americans saw the highest increases in | 17 | | rates of anxiety and depression in 2020.
| 18 | | (C) Data from the Illinois Department of Public | 19 | | Health reveals that Black Illinoisans are hospitalized | 20 | | for opioid overdoses at a rate 6 times higher than | 21 | | white Illinoisans.
| 22 | | (D) In the first half of 2020, the number of | 23 | | suicides among Black Chicagoans had increased 106% | 24 | | from the previous year. Nationally, from 2001 to 2017, | 25 | | suicide rates doubled among Black girls aged 13 to 19 | 26 | | and increased 60% for Black boys of the same age.
|
| | | SB0697 | - 3 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (E) According to the Substance Abuse and Mental | 2 | | Health Services Administration, between 2008 and 2018 | 3 | | there were significant increases in serious mental | 4 | | illness and suicide ideation in Hispanics aged 18 to | 5 | | 25 and there remains a large gap in treatment need | 6 | | among Hispanics.
| 7 | | (5) According the U.S. Center for Disease Control and | 8 | | Prevention, children with adverse childhood experiences | 9 | | are more likely to experience negative outcomes like | 10 | | post-traumatic stress disorder, increased anxiety and | 11 | | depression, suicide, and substance use. A 2020 report from | 12 | | Mental Health America shows that 62.1% of Illinois youth | 13 | | with severe depression do not receive any mental health | 14 | | treatment. Survey results found that 80% of college | 15 | | students report that COVID-19 has negatively impacted | 16 | | their mental health.
| 17 | | (6) In rural communities, between 2001 and 2015, the | 18 | | suicide rate increased by 27%, and between 1999 and 2015 | 19 | | the overdose rate increased 325%.
| 20 | | (7) According to the U.S. Department of Veterans | 21 | | Affairs, 154 veterans died by suicide in 2018, which | 22 | | accounts for more than 10% of all suicide deaths reported | 23 | | by the Illinois Department of Public Health in the same | 24 | | year, despite only accounting for approximately 5.7% of | 25 | | the State's total population. Nationally, between 2008 and | 26 | | 2017, more than 6,000 veterans died by suicide each year.
|
| | | SB0697 | - 4 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (8) According to the National Alliance on Mental | 2 | | Illness, 2,000,000 people with mental illness are | 3 | | incarcerated every year, where they do not receive the | 4 | | treatment they need.
| 5 | | (b) A recent landmark federal court ruling offers a | 6 | | concrete demonstration of how the mental health and addiction | 7 | | crisis described in subsection (a) is worsened through the | 8 | | denial of medically necessary mental health and substance use | 9 | | disorder treatment.
| 10 | | (1) In March 2019, the United States District Court of | 11 | | the Northern District of California ruled in Wit v. United | 12 | | Behavioral Health, 2019 WL 1033730 (Wit; N.D.CA Mar. 5, | 13 | | 2019), that United Behavioral Health created flawed level | 14 | | of care placement criteria that were inconsistent with | 15 | | generally accepted standards of mental health and | 16 | | substance use disorder care in order to "mitigate" the | 17 | | requirements of the federal Mental Health Parity and | 18 | | Addiction Equity Act of 2008.
| 19 | | (2) As described by the federal court in Wit, the 8 | 20 | | generally accepted standards of mental health and | 21 | | substance use disorder care require all of the following:
| 22 | | (A) Effective treatment of underlying conditions, | 23 | | rather than mere amelioration of current symptoms, | 24 | | such as suicidality or psychosis.
| 25 | | (B) Treatment of co-occurring behavioral health | 26 | | disorders or medical conditions in a coordinated |
| | | SB0697 | - 5 - | LRB102 17144 BMS 22576 b |
|
| 1 | | manner.
| 2 | | (C) Treatment at the least intensive and | 3 | | restrictive level of care that is safe and effective | 4 | | and meets the needs of the patient's condition; a | 5 | | lower level or less intensive care is appropriate only | 6 | | if it safe and just as effective as treatment at a | 7 | | higher level or service intensity.
| 8 | | (D) Erring on the side of caution, by placing | 9 | | patients in higher levels of care when there is | 10 | | ambiguity as to the appropriate level of care, or when | 11 | | the recommended level of care is not available.
| 12 | | (E) Treatment to maintain functioning or prevent | 13 | | deterioration.
| 14 | | (F) Treatment of mental health and substance use | 15 | | disorders for an appropriate duration based on | 16 | | individual patient needs rather than on specific time | 17 | | limits.
| 18 | | (G) Accounting for the unique needs of children | 19 | | and adolescents when making level of care decisions.
| 20 | | (H) Applying multidimensional assessments of | 21 | | patient needs when making determinations regarding the | 22 | | appropriate level of care.
| 23 | | (3) The court in Wit found that all parties' expert | 24 | | witnesses regarded the American Society of Addiction | 25 | | Medicine (ASAM) criteria for substance use disorders and | 26 | | Level of Care Utilization System (LOCUS), Child and |
| | | SB0697 | - 6 - | LRB102 17144 BMS 22576 b |
|
| 1 | | Adolescent Level of Care Utilization System (CALOCUS), | 2 | | Child and Adolescent Service Intensity Instrument (CASII), | 3 | | and Early Childhood Service Intensity Instrument (ECSII) | 4 | | criteria for mental health disorders as prime examples of | 5 | | level of care criteria that are fully consistent with | 6 | | generally accepted standards of mental health and | 7 | | substance use care.
| 8 | | (4) In particular, the coverage of intermediate levels | 9 | | of care, such as residential treatment, which are | 10 | | essential components of the level of care continuum called | 11 | | for by nonprofit, and clinical specialty associations such | 12 | | as the American Society of Addiction Medicine, are often | 13 | | denied through overly restrictive medical necessity | 14 | | determinations.
| 15 | | (5) On November 3, 2020, the court issued a remedies | 16 | | order requiring United Behavioral Health to reprocess | 17 | | 67,000 mental health and substance use disorder claims and | 18 | | mandating that, for the next decade, United Behavioral | 19 | | Health must use the relevant nonprofit clinical society | 20 | | guidelines for its medical necessity determinations.
| 21 | | (6) The court's findings also demonstrated how United | 22 | | Behavioral Health was in violation of Section 370c of the | 23 | | Illinois Insurance Code for its failure to use the | 24 | | American Society of Addiction Medicine Criteria for | 25 | | substance use disorders. The results of market conduct | 26 | | examinations released by the Illinois Department of |
| | | SB0697 | - 7 - | LRB102 17144 BMS 22576 b |
|
| 1 | | Insurance on July 15, 2020 confirmed these findings citing | 2 | | United Healthcare and CIGNA for their failure to use the | 3 | | American Society of Addiction Medicine Criteria when | 4 | | making medical necessity determinations for substance use | 5 | | disorders as required by Illinois law.
| 6 | | (c) Insurers should not be permitted to deny medically | 7 | | necessary mental health and substance use disorder care | 8 | | through the use of utilization review practices and criteria | 9 | | that are inconsistent with generally accepted standards of | 10 | | mental health and substance use disorder care.
| 11 | | (1) Illinois parity law (Sections 370c and 370c.1 of | 12 | | the Illinois Insurance Code) requires that health plans | 13 | | treat illnesses of the brain, such as addiction and | 14 | | depression, the same way they treat illness of other parts | 15 | | of the body, such as cancer and diabetes. The Illinois | 16 | | General Assembly significantly strengthened Illinois' | 17 | | parity law, which incorporates provisions of the federal | 18 | | Paul Wellstone and Pete Domenici Mental Health Parity and | 19 | | Addiction Equity Act of 2008, in both 2015 and 2018.
| 20 | | (2) While the federal Patient Protection and | 21 | | Affordable Care Act includes mental health and addiction | 22 | | coverage as one of the 10 essential health benefits, it | 23 | | does not contain a definition for medical necessity, and | 24 | | despite the Patient Protection and Affordable Care Act, | 25 | | needed mental health and addiction coverage can be denied | 26 | | through overly restrictive medical necessity |
| | | SB0697 | - 8 - | LRB102 17144 BMS 22576 b |
|
| 1 | | determinations.
| 2 | | (3) Despite the strong actions taken by the Illinois | 3 | | General Assembly, the court in Wit v. United Behavioral | 4 | | Health demonstrated how insurers can mitigate compliance | 5 | | with parity laws due by denying medically necessary mental | 6 | | health and treatment by using flawed medical necessity | 7 | | criteria.
| 8 | | (4) When medically necessary mental health and | 9 | | substance use disorder care is denied, the manifestations | 10 | | of the mental health and addiction crisis described in | 11 | | subsection (a) are severely exacerbated. Individuals with | 12 | | mental health and substance use disorders often have their | 13 | | conditions worsen, sometimes ending up in the criminal | 14 | | justice system or on the streets, resulting in increased | 15 | | emergency hospitalizations, harm to individuals and | 16 | | communities, and higher costs to taxpayers.
| 17 | | (5) In order to realize the promise of mental health | 18 | | and addiction parity and remove barriers to mental health | 19 | | and substance use disorder care for all Illinoisans, | 20 | | insurers must be required to cover medically necessary | 21 | | mental health and substance use disorder care and follow | 22 | | generally accepted standards of mental health and | 23 | | substance use disorder care. | 24 | | Section 5. The Illinois Insurance Code is amended by | 25 | | changing Section 370c as follows:
|
| | | SB0697 | - 9 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (215 ILCS 5/370c) (from Ch. 73, par. 982c)
| 2 | | Sec. 370c. Mental and emotional disorders.
| 3 | | (a)(1) On and after the effective date of this amendatory | 4 | | Act of the 102nd General Assembly January 1, 2019 (the | 5 | | effective date of this amendatory Act of the 101st General | 6 | | Assembly Public Act 100-1024) ,
every insurer that amends, | 7 | | delivers, issues, or renews
group accident and health policies | 8 | | providing coverage for hospital or medical treatment or
| 9 | | services for illness on an expense-incurred basis shall | 10 | | provide coverage for the medically necessary treatment of | 11 | | reasonable and necessary treatment and services
for mental, | 12 | | emotional, nervous, or substance use disorders or conditions | 13 | | consistent with the parity requirements of Section 370c.1 of | 14 | | this Code.
| 15 | | (2) Each insured that is covered for mental, emotional, | 16 | | nervous, or substance use
disorders or conditions shall be | 17 | | free to select the physician licensed to
practice medicine in | 18 | | all its branches, licensed clinical psychologist,
licensed | 19 | | clinical social worker, licensed clinical professional | 20 | | counselor, licensed marriage and family therapist, licensed | 21 | | speech-language pathologist, or other licensed or certified | 22 | | professional at a program licensed pursuant to the Substance | 23 | | Use Disorder Act of
his or her choice to treat such disorders, | 24 | | and
the insurer shall pay the covered charges of such | 25 | | physician licensed to
practice medicine in all its branches, |
| | | SB0697 | - 10 - | LRB102 17144 BMS 22576 b |
|
| 1 | | licensed clinical psychologist,
licensed clinical social | 2 | | worker, licensed clinical professional counselor, licensed | 3 | | marriage and family therapist, licensed speech-language | 4 | | pathologist, or other licensed or certified professional at a | 5 | | program licensed pursuant to the Substance Use Disorder Act up
| 6 | | to the limits of coverage, provided (i)
the disorder or | 7 | | condition treated is covered by the policy, and (ii) the
| 8 | | physician, licensed psychologist, licensed clinical social | 9 | | worker, licensed
clinical professional counselor, licensed | 10 | | marriage and family therapist, licensed speech-language | 11 | | pathologist, or other licensed or certified professional at a | 12 | | program licensed pursuant to the Substance Use Disorder Act is
| 13 | | authorized to provide said services under the statutes of this | 14 | | State and in
accordance with accepted principles of his or her | 15 | | profession.
| 16 | | (3) Insofar as this Section applies solely to licensed | 17 | | clinical social
workers, licensed clinical professional | 18 | | counselors, licensed marriage and family therapists, licensed | 19 | | speech-language pathologists, and other licensed or certified | 20 | | professionals at programs licensed pursuant to the Substance | 21 | | Use Disorder Act, those persons who may
provide services to | 22 | | individuals shall do so
after the licensed clinical social | 23 | | worker, licensed clinical professional
counselor, licensed | 24 | | marriage and family therapist, licensed speech-language | 25 | | pathologist, or other licensed or certified professional at a | 26 | | program licensed pursuant to the Substance Use Disorder Act |
| | | SB0697 | - 11 - | LRB102 17144 BMS 22576 b |
|
| 1 | | has informed the patient of the
desirability of the patient | 2 | | conferring with the patient's primary care
physician.
| 3 | | (4) "Mental, emotional, nervous, or substance use disorder | 4 | | or condition" means a condition or disorder that involves a | 5 | | mental health condition or substance use disorder that falls | 6 | | under any of the diagnostic categories listed in the mental | 7 | | and behavioral disorders chapter of the current edition of the | 8 | | World Health Organization's International Classification of | 9 | | Disease or that is listed in the most recent version of the | 10 | | American Psychiatric Association's Diagnostic and Statistical | 11 | | Manual of Mental Disorders. Changes in terminology, | 12 | | organization, or classification of mental, emotional, nervous, | 13 | | or substance use disorder or condition in future versions of | 14 | | the American Psychiatric Association's Diagnostic and | 15 | | Statistical Manual of Mental Disorders or the World Health | 16 | | Organization's International Statistical Classification of | 17 | | Diseases and Related Health Problems shall not affect the | 18 | | conditions covered by this Section as long as a condition is | 19 | | commonly understood to be a mental, emotional, nervous, or | 20 | | substance use disorder or condition by health care providers | 21 | | practicing in relevant clinical specialties. "Mental, | 22 | | emotional, nervous, or substance use disorder or condition" | 23 | | includes any mental health condition that occurs during | 24 | | pregnancy or during the postpartum period and includes, but is | 25 | | not limited to, postpartum depression. | 26 | | (5) Medically necessary treatment and medical necessity |
| | | SB0697 | - 12 - | LRB102 17144 BMS 22576 b |
|
| 1 | | determinations shall be interpreted and made in a manner that | 2 | | is consistent with and pursuant to subsections (h) through | 3 | | (t). | 4 | | (b)(1) (Blank).
| 5 | | (2) (Blank).
| 6 | | (2.5) (Blank). | 7 | | (3) Unless otherwise prohibited by federal law and | 8 | | consistent with the parity requirements of Section 370c.1 of | 9 | | this Code, the reimbursing insurer that amends, delivers, | 10 | | issues, or renews a group or individual policy of accident and | 11 | | health insurance, a qualified health plan offered through the | 12 | | health insurance marketplace, or a provider of treatment of | 13 | | mental, emotional, nervous,
or substance use disorders or | 14 | | conditions shall furnish medical records or other necessary | 15 | | data
that substantiate that initial or continued treatment is | 16 | | at all times medically
necessary. An insurer shall provide a | 17 | | mechanism for the timely review by a
provider holding the same | 18 | | license and practicing in the same specialty as the
patient's | 19 | | provider, who is unaffiliated with the insurer, jointly | 20 | | selected by
the patient (or the patient's next of kin or legal | 21 | | representative if the
patient is unable to act for himself or | 22 | | herself), the patient's provider, and
the insurer in the event | 23 | | of a dispute between the insurer and patient's
provider | 24 | | regarding the medical necessity of a treatment proposed by a | 25 | | patient's
provider. If the reviewing provider determines the | 26 | | treatment to be medically
necessary, the insurer shall provide |
| | | SB0697 | - 13 - | LRB102 17144 BMS 22576 b |
|
| 1 | | reimbursement for the treatment. Future
contractual or | 2 | | employment actions by the insurer regarding the patient's
| 3 | | provider may not be based on the provider's participation in | 4 | | this procedure.
Nothing prevents
the insured from agreeing in | 5 | | writing to continue treatment at his or her
expense. When | 6 | | making a determination of the medical necessity for a | 7 | | treatment
modality for mental, emotional, nervous, or | 8 | | substance use disorders or conditions, an insurer must make | 9 | | the determination in a
manner that is consistent with the | 10 | | manner used to make that determination with
respect to other | 11 | | diseases or illnesses covered under the policy, including an
| 12 | | appeals process. Medical necessity determinations for | 13 | | substance use disorders shall be made in accordance with | 14 | | appropriate patient placement criteria established by the | 15 | | American Society of Addiction Medicine. No additional criteria | 16 | | may be used to make medical necessity determinations for | 17 | | substance use disorders.
| 18 | | (4) A group health benefit plan amended, delivered, | 19 | | issued, or renewed on or after January 1, 2019 (the effective | 20 | | date of Public Act 100-1024) or an individual policy of | 21 | | accident and health insurance or a qualified health plan | 22 | | offered through the health insurance marketplace amended, | 23 | | delivered, issued, or renewed on or after January 1, 2019 (the | 24 | | effective date of Public Act 100-1024):
| 25 | | (A) shall provide coverage based upon medical | 26 | | necessity for the
treatment of a mental, emotional, |
| | | SB0697 | - 14 - | LRB102 17144 BMS 22576 b |
|
| 1 | | nervous, or substance use disorder or condition consistent | 2 | | with the parity requirements of Section 370c.1 of this | 3 | | Code; provided, however, that in each calendar year | 4 | | coverage shall not be less than the following:
| 5 | | (i) 45 days of inpatient treatment; and
| 6 | | (ii) beginning on June 26, 2006 (the effective | 7 | | date of Public Act 94-921), 60 visits for outpatient | 8 | | treatment including group and individual
outpatient | 9 | | treatment; and | 10 | | (iii) for plans or policies delivered, issued for | 11 | | delivery, renewed, or modified after January 1, 2007 | 12 | | (the effective date of Public Act 94-906),
20 | 13 | | additional outpatient visits for speech therapy for | 14 | | treatment of pervasive developmental disorders that | 15 | | will be in addition to speech therapy provided | 16 | | pursuant to item (ii) of this subparagraph (A); and
| 17 | | (B) may not include a lifetime limit on the number of | 18 | | days of inpatient
treatment or the number of outpatient | 19 | | visits covered under the plan.
| 20 | | (C) (Blank).
| 21 | | (5) An issuer of a group health benefit plan or an | 22 | | individual policy of accident and health insurance or a | 23 | | qualified health plan offered through the health insurance | 24 | | marketplace may not count toward the number
of outpatient | 25 | | visits required to be covered under this Section an outpatient
| 26 | | visit for the purpose of medication management and shall cover |
| | | SB0697 | - 15 - | LRB102 17144 BMS 22576 b |
|
| 1 | | the outpatient
visits under the same terms and conditions as | 2 | | it covers outpatient visits for
the treatment of physical | 3 | | illness.
| 4 | | (5.5) An individual or group health benefit plan amended, | 5 | | delivered, issued, or renewed on or after September 9, 2015 | 6 | | (the effective date of Public Act 99-480) shall offer coverage | 7 | | for medically necessary acute treatment services and medically | 8 | | necessary clinical stabilization services. The treating | 9 | | provider shall base all treatment recommendations and the | 10 | | health benefit plan shall base all medical necessity | 11 | | determinations for substance use disorders in accordance with | 12 | | the most current edition of the Treatment Criteria for | 13 | | Addictive, Substance-Related, and Co-Occurring Conditions | 14 | | established by the American Society of Addiction Medicine. The | 15 | | treating provider shall base all treatment recommendations and | 16 | | the health benefit plan shall base all medical necessity | 17 | | determinations for medication-assisted treatment in accordance | 18 | | with the most current Treatment Criteria for Addictive, | 19 | | Substance-Related, and Co-Occurring Conditions established by | 20 | | the American Society of Addiction Medicine. | 21 | | As used in this subsection: | 22 | | "Acute treatment services" means 24-hour medically | 23 | | supervised addiction treatment that provides evaluation and | 24 | | withdrawal management and may include biopsychosocial | 25 | | assessment, individual and group counseling, psychoeducational | 26 | | groups, and discharge planning. |
| | | SB0697 | - 16 - | LRB102 17144 BMS 22576 b |
|
| 1 | | "Clinical stabilization services" means 24-hour treatment, | 2 | | usually following acute treatment services for substance | 3 | | abuse, which may include intensive education and counseling | 4 | | regarding the nature of addiction and its consequences, | 5 | | relapse prevention, outreach to families and significant | 6 | | others, and aftercare planning for individuals beginning to | 7 | | engage in recovery from addiction. | 8 | | (6) An issuer of a group health benefit
plan may provide or | 9 | | offer coverage required under this Section through a
managed | 10 | | care plan.
| 11 | | (6.5) An individual or group health benefit plan amended, | 12 | | delivered, issued, or renewed on or after January 1, 2019 (the | 13 | | effective date of Public Act 100-1024): | 14 | | (A) shall not impose prior authorization requirements, | 15 | | other than those established under the Treatment Criteria | 16 | | for Addictive, Substance-Related, and Co-Occurring | 17 | | Conditions established by the American Society of | 18 | | Addiction Medicine, on a prescription medication approved | 19 | | by the United States Food and Drug Administration that is | 20 | | prescribed or administered for the treatment of substance | 21 | | use disorders; | 22 | | (B) shall not impose any step therapy requirements, | 23 | | other than those established under the Treatment Criteria | 24 | | for Addictive, Substance-Related, and Co-Occurring | 25 | | Conditions established by the American Society of | 26 | | Addiction Medicine, before authorizing coverage for a |
| | | SB0697 | - 17 - | LRB102 17144 BMS 22576 b |
|
| 1 | | prescription medication approved by the United States Food | 2 | | and Drug Administration that is prescribed or administered | 3 | | for the treatment of substance use disorders; | 4 | | (C) shall place all prescription medications approved | 5 | | by the United States Food and Drug Administration | 6 | | prescribed or administered for the treatment of substance | 7 | | use disorders on, for brand medications, the lowest tier | 8 | | of the drug formulary developed and maintained by the | 9 | | individual or group health benefit plan that covers brand | 10 | | medications and, for generic medications, the lowest tier | 11 | | of the drug formulary developed and maintained by the | 12 | | individual or group health benefit plan that covers | 13 | | generic medications; and | 14 | | (D) shall not exclude coverage for a prescription | 15 | | medication approved by the United States Food and Drug | 16 | | Administration for the treatment of substance use | 17 | | disorders and any associated counseling or wraparound | 18 | | services on the grounds that such medications and services | 19 | | were court ordered. | 20 | | (7) (Blank).
| 21 | | (8)
(Blank).
| 22 | | (9) With respect to all mental, emotional, nervous, or | 23 | | substance use disorders or conditions, coverage for inpatient | 24 | | treatment shall include coverage for treatment in a | 25 | | residential treatment center certified or licensed by the | 26 | | Department of Public Health or the Department of Human |
| | | SB0697 | - 18 - | LRB102 17144 BMS 22576 b |
|
| 1 | | Services. | 2 | | (c) This Section shall not be interpreted to require | 3 | | coverage for speech therapy or other habilitative services for | 4 | | those individuals covered under Section 356z.15
of this Code. | 5 | | (d) With respect to a group or individual policy of | 6 | | accident and health insurance or a qualified health plan | 7 | | offered through the health insurance marketplace, the | 8 | | Department and, with respect to medical assistance, the | 9 | | Department of Healthcare and Family Services shall each | 10 | | enforce the requirements of this Section and Sections 356z.23 | 11 | | and 370c.1 of this Code, the Paul Wellstone and Pete Domenici | 12 | | Mental Health Parity and Addiction Equity Act of 2008, 42 | 13 | | U.S.C. 18031(j), and any amendments to, and federal guidance | 14 | | or regulations issued under, those Acts, including, but not | 15 | | limited to, final regulations issued under the Paul Wellstone | 16 | | and Pete Domenici Mental Health Parity and Addiction Equity | 17 | | Act of 2008 and final regulations applying the Paul Wellstone | 18 | | and Pete Domenici Mental Health Parity and Addiction Equity | 19 | | Act of 2008 to Medicaid managed care organizations, the | 20 | | Children's Health Insurance Program, and alternative benefit | 21 | | plans. Specifically, the Department and the Department of | 22 | | Healthcare and Family Services shall take action: | 23 | | (1) proactively ensuring compliance by individual and | 24 | | group policies, including by requiring that insurers | 25 | | submit comparative analyses, as set forth in paragraph (6) | 26 | | of subsection (k) of Section 370c.1, demonstrating how |
| | | SB0697 | - 19 - | LRB102 17144 BMS 22576 b |
|
| 1 | | they design and apply nonquantitative treatment | 2 | | limitations, both as written and in operation, for mental, | 3 | | emotional, nervous, or substance use disorder or condition | 4 | | benefits as compared to how they design and apply | 5 | | nonquantitative treatment limitations, as written and in | 6 | | operation, for medical and surgical benefits; | 7 | | (2) evaluating all consumer or provider complaints | 8 | | regarding mental, emotional, nervous, or substance use | 9 | | disorder or condition coverage for possible parity | 10 | | violations; | 11 | | (3) performing parity compliance market conduct | 12 | | examinations or, in the case of the Department of | 13 | | Healthcare and Family Services, parity compliance audits | 14 | | of individual and group plans and policies, including, but | 15 | | not limited to, reviews of: | 16 | | (A) nonquantitative treatment limitations, | 17 | | including, but not limited to, prior authorization | 18 | | requirements, concurrent review, retrospective review, | 19 | | step therapy, network admission standards, | 20 | | reimbursement rates, and geographic restrictions; | 21 | | (B) denials of authorization, payment, and | 22 | | coverage; and | 23 | | (C) other specific criteria as may be determined | 24 | | by the Department. | 25 | | The findings and the conclusions of the parity compliance | 26 | | market conduct examinations and audits shall be made public. |
| | | SB0697 | - 20 - | LRB102 17144 BMS 22576 b |
|
| 1 | | The Director may adopt rules to effectuate any provisions | 2 | | of the Paul Wellstone and Pete Domenici Mental Health Parity | 3 | | and Addiction Equity Act of 2008 that relate to the business of | 4 | | insurance. | 5 | | (e) Availability of plan information. | 6 | | (1) The criteria for medical necessity determinations | 7 | | made under a group health plan, an individual policy of | 8 | | accident and health insurance, or a qualified health plan | 9 | | offered through the health insurance marketplace with | 10 | | respect to mental health or substance use disorder | 11 | | benefits (or health insurance coverage offered in | 12 | | connection with the plan with respect to such benefits) | 13 | | must be made available by the plan administrator (or the | 14 | | health insurance issuer offering such coverage) to any | 15 | | current or potential participant, beneficiary, or | 16 | | contracting provider upon request. | 17 | | (2) The reason for any denial under a group health | 18 | | benefit plan, an individual policy of accident and health | 19 | | insurance, or a qualified health plan offered through the | 20 | | health insurance marketplace (or health insurance coverage | 21 | | offered in connection with such plan or policy) of | 22 | | reimbursement or payment for services with respect to | 23 | | mental, emotional, nervous, or substance use disorders or | 24 | | conditions benefits in the case of any participant or | 25 | | beneficiary must be made available within a reasonable | 26 | | time and in a reasonable manner and in readily |
| | | SB0697 | - 21 - | LRB102 17144 BMS 22576 b |
|
| 1 | | understandable language by the plan administrator (or the | 2 | | health insurance issuer offering such coverage) to the | 3 | | participant or beneficiary upon request. | 4 | | (f) As used in this Section, "group policy of accident and | 5 | | health insurance" and "group health benefit plan" includes (1) | 6 | | State-regulated employer-sponsored group health insurance | 7 | | plans written in Illinois or which purport to provide coverage | 8 | | for a resident of this State; and (2) State employee health | 9 | | plans. | 10 | | (g) (1) As used in this subsection: | 11 | | "Benefits", with respect to insurers, means
the benefits | 12 | | provided for treatment services for inpatient and outpatient | 13 | | treatment of substance use disorders or conditions at American | 14 | | Society of Addiction Medicine levels of treatment 2.1 | 15 | | (Intensive Outpatient), 2.5 (Partial Hospitalization), 3.1 | 16 | | (Clinically Managed Low-Intensity Residential), 3.3 | 17 | | (Clinically Managed Population-Specific High-Intensity | 18 | | Residential), 3.5 (Clinically Managed High-Intensity | 19 | | Residential), and 3.7 (Medically Monitored Intensive | 20 | | Inpatient) and OMT (Opioid Maintenance Therapy) services. | 21 | | "Benefits", with respect to managed care organizations, | 22 | | means the benefits provided for treatment services for | 23 | | inpatient and outpatient treatment of substance use disorders | 24 | | or conditions at American Society of Addiction Medicine levels | 25 | | of treatment 2.1 (Intensive Outpatient), 2.5 (Partial | 26 | | Hospitalization), 3.5 (Clinically Managed High-Intensity |
| | | SB0697 | - 22 - | LRB102 17144 BMS 22576 b |
|
| 1 | | Residential), and 3.7 (Medically Monitored Intensive | 2 | | Inpatient) and OMT (Opioid Maintenance Therapy) services. | 3 | | "Substance use disorder treatment provider or facility" | 4 | | means a licensed physician, licensed psychologist, licensed | 5 | | psychiatrist, licensed advanced practice registered nurse, or | 6 | | licensed, certified, or otherwise State-approved facility or | 7 | | provider of substance use disorder treatment. | 8 | | (2) A group health insurance policy, an individual health | 9 | | benefit plan, or qualified health plan that is offered through | 10 | | the health insurance marketplace, small employer group health | 11 | | plan, and large employer group health plan that is amended, | 12 | | delivered, issued, executed, or renewed in this State, or | 13 | | approved for issuance or renewal in this State, on or after | 14 | | January 1, 2019 (the effective date of Public Act 100-1023) | 15 | | shall comply with the requirements of this Section and Section | 16 | | 370c.1. The services for the treatment and the ongoing | 17 | | assessment of the patient's progress in treatment shall follow | 18 | | the requirements of 77 Ill. Adm. Code 2060. | 19 | | (3) Prior authorization shall not be utilized for the | 20 | | benefits under this subsection. The substance use disorder | 21 | | treatment provider or facility shall notify the insurer of the | 22 | | initiation of treatment. For an insurer that is not a managed | 23 | | care organization, the substance use disorder treatment | 24 | | provider or facility notification shall occur for the | 25 | | initiation of treatment of the covered person within 2 | 26 | | business days. For managed care organizations, the substance |
| | | SB0697 | - 23 - | LRB102 17144 BMS 22576 b |
|
| 1 | | use disorder treatment provider or facility notification shall | 2 | | occur in accordance with the protocol set forth in the | 3 | | provider agreement for initiation of treatment within 24 | 4 | | hours. If the managed care organization is not capable of | 5 | | accepting the notification in accordance with the contractual | 6 | | protocol during the 24-hour period following admission, the | 7 | | substance use disorder treatment provider or facility shall | 8 | | have one additional business day to provide the notification | 9 | | to the appropriate managed care organization. Treatment plans | 10 | | shall be developed in accordance with the requirements and | 11 | | timeframes established in 77 Ill. Adm. Code 2060. If the | 12 | | substance use disorder treatment provider or facility fails to | 13 | | notify the insurer of the initiation of treatment in | 14 | | accordance with these provisions, the insurer may follow its | 15 | | normal prior authorization processes. | 16 | | (4) For an insurer that is not a managed care | 17 | | organization, if an insurer determines that benefits are no | 18 | | longer medically necessary, the insurer shall notify the | 19 | | covered person, the covered person's authorized | 20 | | representative, if any, and the covered person's health care | 21 | | provider in writing of the covered person's right to request | 22 | | an external review pursuant to the Health Carrier External | 23 | | Review Act. The notification shall occur within 24 hours | 24 | | following the adverse determination. | 25 | | Pursuant to the requirements of the Health Carrier | 26 | | External Review Act, the covered person or the covered |
| | | SB0697 | - 24 - | LRB102 17144 BMS 22576 b |
|
| 1 | | person's authorized representative may request an expedited | 2 | | external review.
An expedited external review may not occur if | 3 | | the substance use disorder treatment provider or facility | 4 | | determines that continued treatment is no longer medically | 5 | | necessary. Under this subsection, a request for expedited | 6 | | external review must be initiated within 24 hours following | 7 | | the adverse determination notification by the insurer. Failure | 8 | | to request an expedited external review within 24 hours shall | 9 | | preclude a covered person or a covered person's authorized | 10 | | representative from requesting an expedited external review. | 11 | | If an expedited external review request meets the criteria | 12 | | of the Health Carrier External Review Act, an independent | 13 | | review organization shall make a final determination of | 14 | | medical necessity within 72 hours. If an independent review | 15 | | organization upholds an adverse determination, an insurer | 16 | | shall remain responsible to provide coverage of benefits | 17 | | through the day following the determination of the independent | 18 | | review organization. A decision to reverse an adverse | 19 | | determination shall comply with the Health Carrier External | 20 | | Review Act. | 21 | | (5) The substance use disorder treatment provider or | 22 | | facility shall provide the insurer with 7 business days' | 23 | | advance notice of the planned discharge of the patient from | 24 | | the substance use disorder treatment provider or facility and | 25 | | notice on the day that the patient is discharged from the | 26 | | substance use disorder treatment provider or facility. |
| | | SB0697 | - 25 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (6) The benefits required by this subsection shall be | 2 | | provided to all covered persons with a diagnosis of substance | 3 | | use disorder or conditions. The presence of additional related | 4 | | or unrelated diagnoses shall not be a basis to reduce or deny | 5 | | the benefits required by this subsection. | 6 | | (7) Nothing in this subsection shall be construed to | 7 | | require an insurer to provide coverage for any of the benefits | 8 | | in this subsection. | 9 | | (h) As used in this Section: | 10 | | "Generally accepted standards of mental, emotional, | 11 | | nervous, or substance use disorder or condition care" means | 12 | | standards of care and clinical practice that are generally | 13 | | recognized by health care providers practicing in relevant | 14 | | clinical specialties such as psychiatry, psychology, clinical | 15 | | sociology, social work, addiction medicine and counseling, and | 16 | | behavioral health treatment. Valid, evidence-based sources | 17 | | reflecting generally accepted standards of mental, emotional, | 18 | | nervous, or substance use disorder or condition care include | 19 | | peer-reviewed scientific studies and medical literature, | 20 | | recommendations of nonprofit health care provider professional | 21 | | associations and specialty societies, including, but not | 22 | | limited to, patient placement criteria and clinical practice | 23 | | guidelines, recommendations of federal government agencies, | 24 | | and drug labeling approved by the United States Food and Drug | 25 | | Administration. | 26 | | "Medically necessary treatment of mental, emotional, |
| | | SB0697 | - 26 - | LRB102 17144 BMS 22576 b |
|
| 1 | | nervous, or substance use disorders or conditions" means a | 2 | | service or product addressing the specific needs of that | 3 | | patient, for the purpose of screening, preventing, diagnosing, | 4 | | managing, or treating an illness, injury, condition, or its | 5 | | symptoms, including minimizing the progression of an illness, | 6 | | injury, condition, or its symptoms in a manner that is all of | 7 | | the following: | 8 | | (1) in accordance with the generally accepted | 9 | | standards of mental, emotional, nervous, or substance use | 10 | | disorder or condition care; | 11 | | (2) clinically appropriate in terms of type, | 12 | | frequency, extent, site, and duration; and | 13 | | (3) not primarily for the economic benefit of the | 14 | | insurer, purchaser, or for the convenience of the patient, | 15 | | treating physician, or other health care provider. | 16 | | "Utilization review" means either of the following: | 17 | | (1) prospectively, retrospectively, or concurrently | 18 | | reviewing and approving, modifying, delaying, or denying, | 19 | | based in whole or in part on medical necessity, requests | 20 | | by health care providers, insureds, or their authorized | 21 | | representatives for coverage of health care services | 22 | | before, retrospectively, or concurrently with the | 23 | | provision of health care services to insureds. | 24 | | (2) evaluating the medical necessity, appropriateness, | 25 | | level of care, service intensity, efficacy, or efficiency | 26 | | of health care services, benefits, procedures, or |
| | | SB0697 | - 27 - | LRB102 17144 BMS 22576 b |
|
| 1 | | settings, under any circumstances, to determine whether a | 2 | | health care service or benefit subject to a medical | 3 | | necessity coverage requirement in an insurance policy is | 4 | | covered as medically necessary for an insured. | 5 | | "Utilization review criteria" means patient placement | 6 | | criteria or any criteria, standards, protocols, or guidelines | 7 | | used by an insurer to conduct utilization review. | 8 | | (i)(1) Every insurer that amends, delivers, issues, or | 9 | | renews a group or individual policy of accident and health | 10 | | insurance or a qualified health plan offered through the | 11 | | health insurance marketplace in this State and Medicaid | 12 | | managed care organizations providing coverage for hospital or | 13 | | medical treatment on or after January 1, 2022 shall, pursuant | 14 | | to subsections (h) through (s), provide coverage for medically | 15 | | necessary treatment of mental, emotional, nervous, or | 16 | | substance use disorders or conditions. | 17 | | (2) An insurer shall not limit benefits or coverage for | 18 | | mental, emotional, nervous, or substance use disorders or | 19 | | conditions to short-term or acute treatment at any level of | 20 | | placement. | 21 | | (3) All medical necessity determinations made by the | 22 | | insurer concerning service intensity, level of care placement, | 23 | | continued stay, and transfer or discharge of insureds | 24 | | diagnosed with mental, emotional, nervous, or substance use | 25 | | disorders or conditions shall be conducted in accordance with | 26 | | the requirements of subsections (k) through (u). |
| | | SB0697 | - 28 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (4) An insurer that authorizes a specific type of | 2 | | treatment by a provider pursuant to this Section shall not | 3 | | rescind or modify the authorization after that provider | 4 | | renders the health care service in good faith and pursuant to | 5 | | this authorization for any reason, including, but not limited | 6 | | to, the insurer's subsequent rescission, cancellation, or | 7 | | modification of the insured's or policyholder's contract, or | 8 | | the insured's or policyholder's eligibility. | 9 | | (j) An insurer shall not limit benefits or coverage for | 10 | | medically necessary services on the basis that those services | 11 | | should be or could be covered by a public program, including, | 12 | | but not limited to, special education or an individualized | 13 | | education program, Medicaid, Medicare, Supplemental Security | 14 | | Income, or Social Security Disability Insurance, and shall not | 15 | | include or enforce a contract term that excludes otherwise | 16 | | covered benefits on the basis that those services should be or | 17 | | could be covered by a public program. | 18 | | (k) An insurer shall base any medical necessity | 19 | | determination or the utilization review criteria that the | 20 | | insurer, and any entity acting on the insurer's behalf, | 21 | | applies to determine the medical necessity of health care | 22 | | services and benefits for the diagnosis, prevention, and | 23 | | treatment of mental, emotional, nervous, or substance use | 24 | | disorders or conditions on current generally accepted | 25 | | standards of mental, emotional, nervous, or substance use | 26 | | disorder or condition care. All denials and appeals shall be |
| | | SB0697 | - 29 - | LRB102 17144 BMS 22576 b |
|
| 1 | | reviewed by a professional with experience or expertise | 2 | | comparable to the provider requesting the authorization. | 3 | | (l) In conducting utilization review of all covered health | 4 | | care services and benefits for the diagnosis, prevention, and | 5 | | treatment of mental, emotional, and nervous disorders or | 6 | | conditions in children, adolescents, and adults, an insurer | 7 | | shall exclusively apply the criteria and guidelines set forth | 8 | | in the most recent versions of the treatment criteria | 9 | | developed by the nonprofit professional association for the | 10 | | relevant clinical specialty. Pursuant to subsection (b), in | 11 | | conducting utilization review of all covered services and | 12 | | benefits for the diagnosis, prevention, and treatment of | 13 | | substance use disorders an insurer shall use the most recent | 14 | | edition of the patient placement criteria established by the | 15 | | American Society of Addiction Medicine. | 16 | | (m) In conducting utilization review involving level of | 17 | | care placement decisions or any other patient care decisions | 18 | | that are within the scope of the sources specified in | 19 | | subsection (l), an insurer shall not apply different, | 20 | | additional, conflicting, or more restrictive utilization | 21 | | review criteria than the criteria and guidelines set forth in | 22 | | those sources. For all level of care placement decisions, the | 23 | | insurer shall authorize placement at the level of care | 24 | | consistent with the assessment of the insured using the | 25 | | relevant criteria and guidelines as specified in subsection | 26 | | (l). If that level of placement is not available, the insurer |
| | | SB0697 | - 30 - | LRB102 17144 BMS 22576 b |
|
| 1 | | shall authorize the next higher level of care. In the event of | 2 | | disagreement, the insurer shall provide full detail of its | 3 | | assessment using the relevant criteria and guidelines as | 4 | | specified in subsection (l) to the provider of the service. | 5 | | (n) An insurer shall only engage applicable qualified | 6 | | providers in the treatment of mental, emotional, nervous, or | 7 | | substance use disorders or conditions or the appropriate | 8 | | subspecialty therein and who possess an active professional | 9 | | license or certificate, to review, approve, or deny services. | 10 | | (o) This Section does not in any way limit the rights of a | 11 | | patient under the Medical Patient Rights Act. | 12 | | (p) This Section does not in any way limit early and | 13 | | periodic screening, diagnostic, and treatment benefits as | 14 | | defined under 42 U.S.C. 1396d(r). | 15 | | (q) To ensure the proper use of the criteria described in | 16 | | subsection (l), every insurer shall do all of the following: | 17 | | (1) Sponsor a formal education program by nonprofit | 18 | | clinical specialty associations to educate the insurer's | 19 | | staff, including any third parties contracted with the | 20 | | insurer to review claims, conduct utilization reviews, or | 21 | | make medical necessity determinations about the clinical | 22 | | review criteria. | 23 | | (2) Make the education program available to other | 24 | | stakeholders, including the insurer's participating or | 25 | | contracted providers and potential participants, | 26 | | beneficiaries, or covered lives. The education program |
| | | SB0697 | - 31 - | LRB102 17144 BMS 22576 b |
|
| 1 | | must be provided, at minimum, on a quarterly basis, | 2 | | in-person or digitally, or recordings of the education | 3 | | program must be made available to the aforementioned | 4 | | stakeholders. | 5 | | (3) Provide, at no cost, the clinical review criteria | 6 | | and any training material or resources to providers and | 7 | | insured patients. | 8 | | (4) Track, identify, and analyze how the clinical | 9 | | review criteria are used to certify care, deny care, and | 10 | | support the appeals process. | 11 | | (5) Conduct interrater reliability testing to ensure | 12 | | consistency in utilization review decision making that | 13 | | covers how medical necessity decisions are made; this | 14 | | assessment shall cover all aspects of utilization review | 15 | | as defined in subsection (h). | 16 | | (6) Run interrater reliability reports about how the | 17 | | clinical guidelines are used in conjunction with the | 18 | | utilization review process and parity compliance | 19 | | activities. | 20 | | (7) Achieve interrater reliability pass rates of at | 21 | | least 90% and, if this threshold is not met, immediately | 22 | | provide for the remediation of poor interrater reliability | 23 | | and interrater reliability testing for all new staff | 24 | | before they can conduct utilization review without | 25 | | supervision. | 26 | | (8) Submit to the Department of Insurance or, in the |
| | | SB0697 | - 32 - | LRB102 17144 BMS 22576 b |
|
| 1 | | case of Medicaid managed care organizations, the | 2 | | Department of Healthcare and Family Services every year on | 3 | | or before July 1 results of interrater reliability reports | 4 | | and a summary of the remediation actions taken for those | 5 | | with pass rates lower than 90%. | 6 | | (r) This Section applies to all health care services and | 7 | | benefits for the diagnosis, prevention, and treatment of | 8 | | mental, emotional, nervous, or substance use disorders or | 9 | | conditions covered by an insurance policy, including | 10 | | prescription drugs. | 11 | | (s) This Section applies to an insurer that amends, | 12 | | delivers, issues, or renews a group or individual policy of | 13 | | accident and health insurance or a qualified health plan | 14 | | offered through the health insurance marketplace in this State | 15 | | providing coverage for hospital or medical treatment and | 16 | | conducts utilization review as defined in this Section, | 17 | | including Medicaid managed care organizations, and any entity | 18 | | or contracting provider that performs utilization review or | 19 | | utilization management functions on an insurer's behalf. | 20 | | (t) If the Director determines that an insurer has | 21 | | violated this Section, the Director may, after appropriate | 22 | | notice and opportunity for hearing in accordance with Section | 23 | | 1016 of this Code, by order, assess a civil penalty between | 24 | | $5,000 and $20,000 for each violation. Moneys collected from | 25 | | penalties shall be deposited into the Parity Advancement Fund | 26 | | established in subsection (i) of Section 370c.1. |
| | | SB0697 | - 33 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (u) An insurer shall not adopt, impose, or enforce terms | 2 | | in its policies or provider agreements, in writing or in | 3 | | operation, that undermine, alter, or conflict with the | 4 | | requirements of this Section. | 5 | | (v) The provisions of this Section are severable. If any | 6 | | provision of this Section or its application is held invalid, | 7 | | that invalidity shall not affect other provisions or | 8 | | applications that can be given effect without the invalid | 9 | | provision or application. | 10 | | (Source: P.A. 100-305, eff. 8-24-17; 100-1023, eff. 1-1-19; | 11 | | 100-1024, eff. 1-1-19; 101-81, eff. 7-12-19; 101-386, eff. | 12 | | 8-16-19; revised 9-20-19.) | 13 | | Section 10. The Health Carrier External Review Act is | 14 | | amended by changing Sections 35 and 40 as follows: | 15 | | (215 ILCS 180/35)
| 16 | | Sec. 35. Standard external review. | 17 | | (a) Within 4 months after the date of receipt of a notice | 18 | | of an adverse determination or final adverse determination, a | 19 | | covered person or the covered person's authorized | 20 | | representative may file a request for an external review with | 21 | | the Director. Within one business day after the date of | 22 | | receipt of a request for external review, the Director shall | 23 | | send a copy of the request to the health carrier. | 24 | | (b) Within 5 business days following the date of receipt |
| | | SB0697 | - 34 - | LRB102 17144 BMS 22576 b |
|
| 1 | | of the external review request, the health carrier shall | 2 | | complete a preliminary review of the request to determine | 3 | | whether:
| 4 | | (1) the individual is or was a covered person in the | 5 | | health benefit plan at the time the health care service | 6 | | was requested or at the time the health care service was | 7 | | provided; | 8 | | (2) the health care service that is the subject of the | 9 | | adverse determination or the final adverse determination | 10 | | is a covered service under the covered person's health | 11 | | benefit plan, but the health carrier has determined that | 12 | | the health care service is not covered; | 13 | | (3) the covered person has exhausted the health | 14 | | carrier's internal appeal process unless the covered | 15 | | person is not required to exhaust the health carrier's | 16 | | internal appeal process pursuant to this Act; | 17 | | (4) (blank); and | 18 | | (5) the covered person has provided all the | 19 | | information and forms required to process an external | 20 | | review, as specified in this Act. | 21 | | (c) Within one business day after completion of the | 22 | | preliminary review, the health carrier shall notify the | 23 | | Director and covered person and, if applicable, the covered | 24 | | person's authorized representative in writing whether the | 25 | | request is complete and eligible for external review. If the | 26 | | request: |
| | | SB0697 | - 35 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (1) is not complete, the health carrier shall inform | 2 | | the Director and covered person and, if applicable, the | 3 | | covered person's authorized representative in writing and | 4 | | include in the notice what information or materials are | 5 | | required by this Act to make the request complete; or | 6 | | (2) is not eligible for external review, the health | 7 | | carrier shall inform the Director and covered person and, | 8 | | if applicable, the covered person's authorized | 9 | | representative in writing and include in the notice the | 10 | | reasons for its ineligibility.
| 11 | | The Department may specify the form for the health | 12 | | carrier's notice of initial determination under this | 13 | | subsection (c) and any supporting information to be included | 14 | | in the notice. | 15 | | The notice of initial determination of ineligibility shall | 16 | | include a statement informing the covered person and, if | 17 | | applicable, the covered person's authorized representative | 18 | | that a health carrier's initial determination that the | 19 | | external review request is ineligible for review may be | 20 | | appealed to the Director by filing a complaint with the | 21 | | Director. | 22 | | Notwithstanding a health carrier's initial determination | 23 | | that the request is ineligible for external review, the | 24 | | Director may determine that a request is eligible for external | 25 | | review and require that it be referred for external review. In | 26 | | making such determination, the Director's decision shall be in |
| | | SB0697 | - 36 - | LRB102 17144 BMS 22576 b |
|
| 1 | | accordance with the terms of the covered person's health | 2 | | benefit plan, unless such terms are inconsistent with | 3 | | applicable law, and shall be subject to all applicable | 4 | | provisions of this Act. | 5 | | (d) Whenever the Director receives notice that a request | 6 | | is eligible for external review following the preliminary | 7 | | review conducted pursuant to this Section, within one business | 8 | | day after the date of receipt of the notice, the Director | 9 | | shall: | 10 | | (1) assign an independent review organization from the | 11 | | list of approved independent review organizations compiled | 12 | | and maintained by the Director pursuant to this Act and | 13 | | notify the health carrier of the name of the assigned | 14 | | independent review organization; and | 15 | | (2) notify in writing the covered person and, if | 16 | | applicable, the covered person's authorized representative | 17 | | of the request's eligibility and acceptance for external | 18 | | review and the name of the independent review | 19 | | organization. | 20 | | The Director shall include in the notice provided to the | 21 | | covered person and, if applicable, the covered person's | 22 | | authorized representative a statement that the covered person | 23 | | or the covered person's authorized representative may, within | 24 | | 5 business days following the date of receipt of the notice | 25 | | provided pursuant to item (2) of this subsection (d), submit | 26 | | in writing to the assigned independent review organization |
| | | SB0697 | - 37 - | LRB102 17144 BMS 22576 b |
|
| 1 | | additional information that the independent review | 2 | | organization shall consider when conducting the external | 3 | | review. The independent review organization is not required | 4 | | to, but may, accept and consider additional information | 5 | | submitted after 5 business days. | 6 | | (e) The assignment by the Director of an approved | 7 | | independent review organization to conduct an external review | 8 | | in accordance with this Section shall be done on a random basis | 9 | | among those independent review organizations approved by the | 10 | | Director pursuant to this Act. | 11 | | (f) Within 5 business days after the date of receipt of the | 12 | | notice provided pursuant to item (1) of subsection (d) of this | 13 | | Section, the health carrier or its designee utilization review | 14 | | organization shall provide to the assigned independent review | 15 | | organization the documents and any information considered in | 16 | | making the adverse determination or final adverse | 17 | | determination; in such cases, the following provisions shall | 18 | | apply: | 19 | | (1) Except as provided in item (2) of this subsection | 20 | | (f), failure by the health carrier or its utilization | 21 | | review organization to provide the documents and | 22 | | information within the specified time frame shall not | 23 | | delay the conduct of the external review. | 24 | | (2) If the health carrier or its utilization review | 25 | | organization fails to provide the documents and | 26 | | information within the specified time frame, the assigned |
| | | SB0697 | - 38 - | LRB102 17144 BMS 22576 b |
|
| 1 | | independent review organization may terminate the external | 2 | | review and make a decision to reverse the adverse | 3 | | determination or final adverse determination. | 4 | | (3) Within one business day after making the decision | 5 | | to terminate the external review and make a decision to | 6 | | reverse the adverse determination or final adverse | 7 | | determination under item (2) of this subsection (f), the | 8 | | independent review organization shall notify the Director, | 9 | | the health carrier, the covered person and, if applicable, | 10 | | the covered person's authorized representative, of its | 11 | | decision to reverse the adverse determination. | 12 | | (g) Upon receipt of the information from the health | 13 | | carrier or its utilization review organization, the assigned | 14 | | independent review organization shall review all of the | 15 | | information and documents and any other information submitted | 16 | | in writing to the independent review organization by the | 17 | | covered person and the covered person's authorized | 18 | | representative. | 19 | | (h) Upon receipt of any information submitted by the | 20 | | covered person or the covered person's authorized | 21 | | representative, the independent review organization shall | 22 | | forward the information to the health carrier within 1 | 23 | | business day. | 24 | | (1) Upon receipt of the information, if any, the | 25 | | health carrier may reconsider its adverse determination or | 26 | | final adverse determination that is the subject of the |
| | | SB0697 | - 39 - | LRB102 17144 BMS 22576 b |
|
| 1 | | external review.
| 2 | | (2) Reconsideration by the health carrier of its | 3 | | adverse determination or final adverse determination shall | 4 | | not delay or terminate the external review.
| 5 | | (3) The external review may only be terminated if the | 6 | | health carrier decides, upon completion of its | 7 | | reconsideration, to reverse its adverse determination or | 8 | | final adverse determination and provide coverage or | 9 | | payment for the health care service that is the subject of | 10 | | the adverse determination or final adverse determination. | 11 | | In such cases, the following provisions shall apply: | 12 | | (A) Within one business day after making the | 13 | | decision to reverse its adverse determination or final | 14 | | adverse determination, the health carrier shall notify | 15 | | the Director, the covered person and, if applicable, | 16 | | the covered person's authorized representative, and | 17 | | the assigned independent review organization in | 18 | | writing of its decision. | 19 | | (B) Upon notice from the health carrier that the | 20 | | health carrier has made a decision to reverse its | 21 | | adverse determination or final adverse determination, | 22 | | the assigned independent review organization shall | 23 | | terminate the external review. | 24 | | (i) In addition to the documents and information provided | 25 | | by the health carrier or its utilization review organization | 26 | | and the covered person and the covered person's authorized |
| | | SB0697 | - 40 - | LRB102 17144 BMS 22576 b |
|
| 1 | | representative, if any, the independent review organization, | 2 | | to the extent the information or documents are available and | 3 | | the independent review organization considers them | 4 | | appropriate, shall consider the following in reaching a | 5 | | decision: | 6 | | (1) the covered person's pertinent medical records; | 7 | | (2) the covered person's health care provider's | 8 | | recommendation; | 9 | | (3) consulting reports from appropriate health care | 10 | | providers and other documents submitted by the health | 11 | | carrier or its designee utilization review organization, | 12 | | the covered person, the covered person's authorized | 13 | | representative, or the covered person's treating provider; | 14 | | (4) the terms of coverage under the covered person's | 15 | | health benefit plan with the health carrier to ensure that | 16 | | the independent review organization's decision is not | 17 | | contrary to the terms of coverage under the covered | 18 | | person's health benefit plan with the health carrier, | 19 | | unless the terms are inconsistent with applicable law; | 20 | | (5) the most appropriate practice guidelines, which | 21 | | shall include applicable evidence-based standards and may | 22 | | include any other practice guidelines developed by the | 23 | | federal government, national or professional medical | 24 | | societies, boards, and associations; | 25 | | (6) any applicable clinical review criteria developed | 26 | | and used by the health carrier or its designee utilization |
| | | SB0697 | - 41 - | LRB102 17144 BMS 22576 b |
|
| 1 | | review organization; | 2 | | (7) the opinion of the independent review | 3 | | organization's clinical reviewer or reviewers after | 4 | | considering items (1) through (6) of this subsection (i) | 5 | | to the extent the information or documents are available | 6 | | and the clinical reviewer or reviewers considers the | 7 | | information or documents appropriate; | 8 | | (8) (blank); and | 9 | | (9) in the case of medically necessary determinations | 10 | | for substance use disorders, the patient placement | 11 | | criteria established by the American Society of Addiction | 12 | | Medicine. | 13 | | (i-5) For an adverse determination or final adverse | 14 | | determination involving mental, emotional, nervous, or | 15 | | substance use disorders or conditions, the independent review | 16 | | organization shall: | 17 | | (1) consider the documents and information as set | 18 | | forth in subsection (i), except that all practice | 19 | | guidelines and clinical review criteria must be consistent | 20 | | with the requirements set forth in Section 370c of the | 21 | | Illinois Insurance Code; and | 22 | | (2) make its decision, pursuant to subsection (j), | 23 | | whether to uphold or reverse the adverse determination or | 24 | | final adverse determination based on whether the service | 25 | | constitutes medically necessary treatment of a mental, | 26 | | emotional, nervous, or substance use disorders or |
| | | SB0697 | - 42 - | LRB102 17144 BMS 22576 b |
|
| 1 | | condition as defined in Section 370c of the Illinois | 2 | | Insurance Code. | 3 | | (j) Within 5 days after the date of receipt of all | 4 | | necessary information, but in no event more than 45 days after | 5 | | the date of receipt of the request for an external review, the | 6 | | assigned independent review organization shall provide written | 7 | | notice of its decision to uphold or reverse the adverse | 8 | | determination or the final adverse determination to the | 9 | | Director, the health carrier, the covered person, and, if | 10 | | applicable, the covered person's authorized representative. In | 11 | | reaching a decision, the assigned independent review | 12 | | organization is not bound by any claim determinations reached | 13 | | prior to the submission of information to the independent | 14 | | review organization. In such cases, the following provisions | 15 | | shall apply: | 16 | | (1) The independent review organization shall include | 17 | | in the notice: | 18 | | (A) a general description of the reason for the | 19 | | request for external review; | 20 | | (B) the date the independent review organization | 21 | | received the assignment from the Director to conduct | 22 | | the external review; | 23 | | (C) the time period during which the external | 24 | | review was conducted; | 25 | | (D) references to the evidence or documentation, | 26 | | including the evidence-based standards, considered in |
| | | SB0697 | - 43 - | LRB102 17144 BMS 22576 b |
|
| 1 | | reaching its decision; | 2 | | (E) the date of its decision; | 3 | | (F) the principal reason or reasons for its | 4 | | decision, including what applicable, if any, | 5 | | evidence-based standards that were a basis for its | 6 | | decision; and
| 7 | | (G) the rationale for its decision. | 8 | | (2) (Blank). | 9 | | (3) (Blank). | 10 | | (4) Upon receipt of a notice of a decision reversing | 11 | | the adverse determination or final adverse determination, | 12 | | the health carrier immediately shall approve the coverage | 13 | | that was the subject of the adverse determination or final | 14 | | adverse determination.
| 15 | | (Source: P.A. 99-480, eff. 9-9-15.) | 16 | | (215 ILCS 180/40)
| 17 | | Sec. 40. Expedited external review. | 18 | | (a) A covered person or a covered person's authorized | 19 | | representative may file a request for an expedited external | 20 | | review with the Director either orally or in writing: | 21 | | (1) immediately after the date of receipt of a notice | 22 | | prior to a final adverse determination as provided by | 23 | | subsection (b) of Section 20 of this Act; | 24 | | (2) immediately after the date of receipt of a notice | 25 | | upon final adverse determination as provided by subsection |
| | | SB0697 | - 44 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (c) of Section 20 of this Act; or | 2 | | (3) if a health carrier fails to provide a decision on | 3 | | request for an expedited internal appeal within 48 hours | 4 | | as provided by item (2) of Section 30 of this Act. | 5 | | (b) Upon receipt of a request for an expedited external | 6 | | review, the Director shall immediately send a copy of the | 7 | | request to the health carrier. Immediately upon receipt of the | 8 | | request for an expedited external review, the health carrier | 9 | | shall determine whether the request meets the reviewability | 10 | | requirements set forth in subsection (b) of Section 35. In | 11 | | such cases, the following provisions shall apply: | 12 | | (1) The health carrier shall immediately notify the | 13 | | Director, the covered person, and, if applicable, the | 14 | | covered person's authorized representative of its | 15 | | eligibility determination. | 16 | | (2) The notice of initial determination shall include | 17 | | a statement informing the covered person and, if | 18 | | applicable, the covered person's authorized representative | 19 | | that a health carrier's initial determination that an | 20 | | external review request is ineligible for review may be | 21 | | appealed to the Director. | 22 | | (3) The Director may determine that a request is | 23 | | eligible for expedited external review notwithstanding a | 24 | | health carrier's initial determination that the request is | 25 | | ineligible and require that it be referred for external | 26 | | review. |
| | | SB0697 | - 45 - | LRB102 17144 BMS 22576 b |
|
| 1 | | (4) In making a determination under item (3) of this | 2 | | subsection (b), the Director's decision shall be made in | 3 | | accordance with the terms of the covered person's health | 4 | | benefit plan, unless such terms are inconsistent with | 5 | | applicable law, and shall be subject to all applicable | 6 | | provisions of this Act. | 7 | | (5) The Director may specify the form for the health | 8 | | carrier's notice of initial determination under this | 9 | | subsection (b) and any supporting information to be | 10 | | included in the notice. | 11 | | (c) Upon receipt of the notice that the request meets the | 12 | | reviewability requirements, the Director shall immediately | 13 | | assign an independent review organization from the list of | 14 | | approved independent review organizations compiled and | 15 | | maintained by the Director to conduct the expedited review. In | 16 | | such cases, the following provisions shall apply: | 17 | | (1) The assignment of an approved independent review | 18 | | organization to conduct an external review in accordance | 19 | | with this Section shall be made from those approved | 20 | | independent review organizations qualified to conduct | 21 | | external review as required by Sections 50 and 55 of this | 22 | | Act.
| 23 | | (2) The Director shall immediately notify the health | 24 | | carrier of the name of the assigned independent review | 25 | | organization. Immediately upon receipt from the Director | 26 | | of the name of the independent review organization |
| | | SB0697 | - 46 - | LRB102 17144 BMS 22576 b |
|
| 1 | | assigned to conduct the external review, but in no case | 2 | | more than 24 hours after receiving such notice, the health | 3 | | carrier or its designee utilization review organization | 4 | | shall provide or transmit all necessary documents and | 5 | | information considered in making the adverse determination | 6 | | or final adverse determination to the assigned independent | 7 | | review organization electronically or by telephone or | 8 | | facsimile or any other available expeditious method. | 9 | | (3) If the health carrier or its utilization review | 10 | | organization fails to provide the documents and | 11 | | information within the specified timeframe, the assigned | 12 | | independent review organization may terminate the external | 13 | | review and make a decision to reverse the adverse | 14 | | determination or final adverse determination. | 15 | | (4) Within one business day after making the decision | 16 | | to terminate the external review and make a decision to | 17 | | reverse the adverse determination or final adverse | 18 | | determination under item (3) of this subsection (c), the | 19 | | independent review organization shall notify the Director, | 20 | | the health carrier, the covered person, and, if | 21 | | applicable, the covered person's authorized representative | 22 | | of its decision to reverse the adverse determination or | 23 | | final adverse determination.
| 24 | | (d) In addition to the documents and information provided | 25 | | by the health carrier or its utilization review organization | 26 | | and any documents and information provided by the covered |
| | | SB0697 | - 47 - | LRB102 17144 BMS 22576 b |
|
| 1 | | person and the covered person's authorized representative, the | 2 | | independent review organization, to the extent the information | 3 | | or documents are available and the independent review | 4 | | organization considers them appropriate, shall consider | 5 | | information as required by subsection (i) of Section 35 of | 6 | | this Act in reaching a decision. | 7 | | (d-5) For expedited external reviews involving mental, | 8 | | emotional, nervous, or substance use disorders or conditions, | 9 | | the independent review organization shall consider documents | 10 | | and information and shall make a decision to uphold or reverse | 11 | | the adverse determination or final adverse determination | 12 | | pursuant to subsection (i-5) of Section 35. | 13 | | (e) As expeditiously as the covered person's medical | 14 | | condition or circumstances requires, but in no event more than | 15 | | 72 hours after the date of receipt of the request for an | 16 | | expedited external review, the assigned independent review | 17 | | organization shall: | 18 | | (1) make a decision to uphold or reverse the final | 19 | | adverse determination; and | 20 | | (2) notify the Director, the health carrier, the | 21 | | covered person, the covered person's health care provider, | 22 | | and, if applicable, the covered person's authorized | 23 | | representative, of the decision. | 24 | | (f) In reaching a decision, the assigned independent | 25 | | review organization is not bound by any decisions or | 26 | | conclusions reached during the health carrier's utilization |
| | | SB0697 | - 48 - | LRB102 17144 BMS 22576 b |
|
| 1 | | review process or the health carrier's internal appeal | 2 | | process.
| 3 | | (g) Upon receipt of notice of a decision reversing the | 4 | | adverse determination or final adverse determination, the | 5 | | health carrier shall immediately approve the coverage that was | 6 | | the subject of the adverse determination or final adverse | 7 | | determination. | 8 | | (h) If the notice provided pursuant to subsection (e) of | 9 | | this Section was not in writing, then within 48 hours after the | 10 | | date of providing that notice, the assigned independent review | 11 | | organization shall provide written confirmation of the | 12 | | decision to the Director, the health carrier, the covered | 13 | | person, and, if applicable, the covered person's authorized | 14 | | representative including the information set forth in | 15 | | subsection (j) of Section 35 of this Act as applicable. | 16 | | (i) An expedited external review may not be provided for | 17 | | retrospective adverse or final adverse determinations.
| 18 | | (j) The assignment by the Director of an approved | 19 | | independent review organization to conduct an external review | 20 | | in accordance with this Section shall be done on a random basis | 21 | | among those independent review organizations approved by the | 22 | | Director pursuant to this Act. | 23 | | (Source: P.A. 96-857, eff. 7-1-10; 97-333, eff. 8-12-11; | 24 | | 97-574, eff. 8-26-11.)
| 25 | | Section 99. Effective date. This Act takes effect upon | 26 | | becoming law.
|
|